Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06984627 | A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | PHASE2 | RECRUITING | 30 | — | — | Sep 2, 2025 | Sep 23, 2026 | May 22, 2026 | 13 | Canada, Germany +3 |
Free thyroxine
| Arm | Type | Description |
|---|---|---|
| Rilzabrutinib dose 1 | EXPERIMENTAL | Rilzabrutinib |
| Rilzabrutinib dose 2 | EXPERIMENTAL | Rilzabrutinib |
| Name | Type | Description |
|---|---|---|
| Rilzabrutinib dose 1 | DRUG | Pharmaceutical form:Tablet-Route of administration:Oral |
| Rilzabrutinib dose 2 | DRUG | Pharmaceutical form:Tablet-Route of administration:Oral |
Inclusion Criteria: * Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening. * A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at s...